Heini Honkanen appointed as Medaffcon’s Market Access Lead
Heini Honkanen has been appointed as Medaffcon’s Market Access Lead. The new Market Access Team was created when the previous Price and Reimbursement and HE & Access Teams were merged.
Demonstrating that a health technology, e.g. a product, procedure or any intervention, is worth its cost is in a pivotal role to support access to market, adaptation and positioning. Data on health effects and resources needed to gain those are required to evaluate the efficacy, i.e., cost-effectiveness of new and existing health technologies.
Clinical trials provide information on efficacy and safety profiles of health technologies in controlled trial setting, prior to marketing authorization and real-life use. However, effectiveness and safety in real-life clinical practice and in different patient groups may remain uncertain, or even unknown.
The accumulation of real-world data starts after adaptation of health technologies to clinical practice allowing the identification of patient demographics, treatment pathways, safety profiles, effectiveness and resource use related to disease of interest and its treatments. Using real-world data, subsequently refined into real-world evidence, provides an opportunity to demonstrate the value of health technologies to the patients, health care providers and health care system, and the whole society. Real-world evidence reduces uncertainty related to health technology assessments to the minimum at any stage of the life cycle of the intervention, both pre and post market entry (Figure 1.).
Medaffcon’s Health Economists, Tatu Sainio and Mikko Kosunen, spoke about how real world evidence (RWE) can be utilized in a health technology assessment (HTA) in our annual customer evening. Watch a recording of the speech below.
Heini Honkanen has been appointed as Medaffcon’s Market Access Lead. The new Market Access Team was created when the previous Price and Reimbursement and HE & Access Teams were merged.
Medaffconin Tanja Nieminen ja Heini Honkanen osallistuivat terveystaloustieteen tutkimukseen ja terveydenhuollon menetelmien arviointiin keskittyvään ISPOR-kongressiin marraskuussa.
In health economic studies, real world evidence (RWE) can produce additional knowledge, especially on the...